Teva Pharmaceutical Industries Limited Ordinary Shares (TEVA) stock analysis
TEVA · Teva Pharmaceutical Industries Limited Ordinary Shares
Latest recorded price: USD 42.57
Model-estimated fair value: USD 12.38. This assumption-based estimate is for general research and is not investment advice.
Sector and industry: Healthcare · Drug Manufacturers - Specialty & Generic
At $42.57, TEVA trades 244.0% above the model's base-case value of $12.38. Using Operating FCFF DCF (revenue x margin - reinvestment), the model estimates $9.96 in the conservative case and $15.09 in the optimistic case, with a valuation confidence score of 55/100. About 73% of the value comes from the terminal value, so the result is sensitive to long-term growth and discount-rate assumptions. Fiscal 2025 figures: revenue growth 5.0%, free cash flow margin 6.7%, ROIC 21.7%. The model does not flag any risk signals for this company.